ANA Investigates: A Podcast Series

The latest in neurology and neuroscience, each month from the ANA. ANA members are offered the opportunity to claim AMA PRA Category 1 CreditsTM. Please follow this link to access CME information and instructions.

Latest Episode

Equitable tele-neurologic care starts with first identifying disparities, then identifying how to overcome them – learn about both with Dr. Lee Schwamm on the latest ANA Investigates. Series 3, Episode 11.


  • Guest: Dr. Lee Schwamm, C Miller Fisher Endowed Chair in Vascular Neurology and the Director of the Center for TeleHealth at Massachusetts General Hospital, Professor of Neurology at Harvard Medical School and Vice President for Digital Patient Experience at the Mass General Brigham Health System.
  • Interviewer/Producer: Amanda Jagolino-Cole, Director of the UT Teleneurology Division at McGovern Medical School at the University of Texas Health Science Center in Houston
  • Disclosures: None

Recently Released

Episode Archive

Recent Publications

"ANA Podcasts & Webinars: Basilar Artery Stroke," Michelle C. Johansen MD, PhD,, Carlo W. Cereda MD, Jeremy J. Heit MD, PhD, Annals of Neurology, Volume 91, Issue 4

"ANA Investigates Dysautonomia," Megan Richie MD, Adeline Goss MD, Safwan Jaradeh MD, Annals of Neurology, Volume 91, Issue 1

"ANA Podcasts & Webinars: Neuromodulation in Epilepsy,Rohit R. Das MD, Adeline L. Goss MD, Megan B. Richie MD, Vikram R. Rao MD, PhD, Annals of Neurology, Volume 91, Issue 2


"ANA Investigates Therapeutic Advancements in Neuroimmunology." Samudralwar RD, Goss AL, Richie M, Gelfand JM.Ann Neurol. 2021 Nov;90(5):720-721. doi: 10.1002/ana.26222. Epub 2021 Oct 7.

"ANA Investigates: Neural Circuit Concepts Connecting Neurology and Psychiatry." Das RR, Goss AL, Richie M, Geocadin RG, Mayberg HS.Ann Neurol. 2021 Oct;90(4):568-569. doi: 10.1002/ana.26190. Epub 2021 Aug 24.

ANA Investigates: Tenecteplase.” Johansen MC, Campbell BCV. ANA Investigates: Tenecteplase. Ann Neurol. 2021 Jul;90(1):1-3

ANA Investigates: Neurological Complications of COVID-19 Vaccines.” Goss AL, Samudralwar RD, Das RR, Nath A. Ann Neurol. 2021 May;89(5):856-857.

"ANA Investigates Embolic Stroke of Unknown Source Clinical Trials and Advances in Research," Michelle C. Johansen MD, Romergryko G. Geocadin MD, Hooman Kamel MD, Annals of Neurology, Volume 88, Issue 3

"ANA Investigates: Pioneering Unbiased Diagnostics," Megan Richie MD, Samuel Pleasure MD, PhD, Jennifer Hurley CHCP, CPHQ, Adeline Goss MD, Michael Wilson MD, Annals of Neurology, Volume 87, Issue 3


Full List

ANA Investigates is an Education Innovation Subcommittee Production

ANA Investigates host & executive producer: Adeline Goss, MD, Highland Hospital

ANA Investigates episode producers & planners are members of the Education Innovation Subcommittee:  Romergryko G. Geocadin, MD, Johns Hopkins University; Clifton Gooch, MD, FAAN, University of South Florida; Michelle Johansen, MD, Johns Hopkins University; Danny Bega, MD, MS, Northwestern University; Megan Richie, MD, University of California, San Francisco; Adeline Goss, MD, Highland Hospital; Rohini Samudralwar, University of Texas Health Science Center at Houston; Doug Ney, University of Colorado; Rohit Das, UT Southwestern; and Jen Hurley, CHCP, CPHQ, ANA Accreditation & Education Manager.

Subscribe to ANA Investigates on Apple | Google | Spotify to receive automatic updates when new episodes are released.

Submit ideas for future episodes  


CME Information

Eligible ANA Investigates episodes are designated for AMA PRA Category 1 Credit(s)™. The system to claim CME will open at the end of the year following the last episode of each calendar year. You will have the ability to indicate the episodes for which you are seeking credit in one simple evaluation.

The American Neurological Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).

The planners and faculty for this activity have no relevant relationships to disclose unless listed in the episode show notes. All relevant relationships were mitigated prior to the release of the episode.





  • Equitable tele-neurologic care starts with first identifying disparities, then identifying how to overcome them – learn about both with Dr. Lee Schwamm on the latest ANA Investigates. Series 3, Episode 11. Featuring:

    • Guest: Dr. Lee Schwamm, C Miller Fisher Endowed Chair in Vascular Neurology and the Director of the Center for TeleHealth at Massachusetts General Hospital, Professor of Neurology at Harvard Medical School and Vice President for Digital Patient Experience at the Mass General Brigham Health System.
    • Interviewer/Producer: Amanda Jagolino-Cole, Director of the UT Teleneurology Division at McGovern Medical School at the University of Texas Health Science Center in Houston.
    • Disclosures: None

  • Late last month, the journal Science published an investigative report that accused a much-cited publication in Alzheimer’s disease... of fabricating scientific images. The study under scrutiny was published in Nature in 2006 by Sylvain Lesné and colleagues. It claimed that an amyloid oligomer called Aβ*56 impaired memory in mice. The recent Science report found potential fabrication in the images used in that paper... and concluded that this potential fabrication threatens the amyloid hypothesis in Alzheimer’s disease. Here at ANA Investigates, we decided we needed to ask the experts about that. Their conversation will help us understand the impact of the recent investigative report on the field of Alzheimer’s research. Series 3, Episode 10. Featuring:  - Guest: Dr. Richard O’Brien, Alzheimer’s researcher, Chair of the Department of Neurology at Duke University - Interviewer/Producer: Dr. Erik Roberson, Alzheimer’s researcher, endowed Professor of Neurology, and Director of the Alzheimer’s Disease Center at the University of Alabama at Birmingham

  • Last month on the podcast, we talked about updates in the diagnosis of autoimmune encephalitis. This month we turn to advances in treating autoimmune encephalitis. Treating these conditions has traditionally been practitioner-dependent, and currently no FDA-approved therapies exist. But that’s beginning to change. Series 3, Episode 9. Featuring:

    • Guest: Dr. Maarten Titulaer, Erasmus MC University Medical Center
    • Interviewer/Producer: Dr. Rohini Samudralwar, University of Pennsylvania
    • Disclosures: Dr. Titulaer disclosed that his institution receives consulting funds form UCB, Viela Bio (Horizon), and CSL Behring, he is the co-investigator on the ExTinguish trial funded in part by Horizon, and a PI IVIG trial funded by CSL Behring.

  • On today's episode, Dr. Adeline Goss interviews Dr. Andrew McKeon on updates on diagnostics for part one of a two-part series on autoimmune encephalitis. Series 3, Episode 8. Featuring:

    • Guest: Andrew McKeon, M.B., B.Ch., M.D., Mayo Clinic College of Medicine and Science
    • Interviewer/Producer: Adeline Goss, MD, Highland Hospital
    • Disclosures: Dr. McKeon disclosed that he is a consultant for Johnson & Roche Genentech; and receives royalties from Euroimmun

  • On today's episode, we discuss the term "TIA" and the current debate as it pertains to advances in stroke diagnostics that have led some to propose that we retire the term. Series 3, Episode 7. Featuring:

    • Guest: Clay Johnson, MD, PhD, The University of Texas at Austin
    • Interviewer/Producer: Megan Richie, MD, UCSF

  • Burnt out by talking about burnout? Please join us for a podcast with Dr. Amy Arnsten, Professor of Neuroscience and Psychology at Yale University, to investigate what goes on in the brain that leads to burnout and how this can direct our efforts to reduce burnout. Series 3, Episode 6. Featuring:

    • Guest: Dr. Amy Arnsten, Professor of Neuroscience and Psychology at Yale University -
    • Interviewer/Producer: Dr. Amanda Jagolino-Cole of the McGovern Medical at the University of Texas Health Science Center in Houston

    Dr. Arnsten provided additional resources, and these may be found on the ANA website:

  • On today’s show, we’ll focus on the future of biomarkers in Alzheimer’s disease. We know that amyloid beta and tau protein deposit long before patients with Alzheimer’s develop symptoms. If we could use biomarkers to detect this pathology early, and treat patients early, could we prevent the progression to dementia? Our guests today are leaders in the development of biomarkers for Alzheimer’s disease - Dr. Suzanne Schindler, Associate Professor of Neurology at Washington University in St. Louis and Dr. Gil Rabinovici, Professor of Neurology and Radiology at the University of California San Francisco. They’ll talk with Dr. Doug Ney of UC Denver about the expanding role of biomarkers in Alzheimer’s prevention and treatment. Series 3, Episode 5


    • Guests: Dr. Suzanne Schindler, Washington University at St. Louis & Dr. Gil Rabinovici, University of California at San Francisco
    • Interviewer/Producer: Dr. Douglas Ney, University of Colorado
    • Disclosures: Dr. Schindler disclosed that C2N Diagnostics provided data free of cost for her team to analyze. Dr. Rabinovici disclosed that he leads the New IDEAS study and has received research funding from Avid Radiopharmaceuticals, GE Healthcare, Life Molecular Imaging, Genentech; and is on scientific advisory boards for Eisai, J&J, Genentech, Eli Lilly, and Roche.

  • Can coma be “cured”? On this podcast, we talk to Dr. Claude Hemphill and Dr. Romer Geocadin of the Curing Coma Campaign. Series 3, Episode 4


    • Guests: Romer Geocadin, MD, Johns Hopkins University & Claude Hemphill, MD, University of California San Francisco
    • Interviewer/Producer: Dr. Adeline Goss

    Below are articles the guests of this podcast wished to share with the listeners:

    • Early Thalamocortical Reperfusion Leads to Neurologic Recovery in a Rodent Cardiac Arrest Model:
    • Proceedings of the First Curing Coma Campaign NIH Symposium: Challenging the Future of Research for Coma and Disorders of Consciousness:
    • AHA SCIENTIFIC STATEMENT: Standards for Studies of Neurological Prognostication in Comatose Survivors of Cardiac Arrest: Circulation. 2019;140:e517–e542. DOI: 10.1161/CIR.0000000000000702 -
    • Detection of Brain Activation in Unresponsive Patients with Acute Brain Injury; n engl j med 380;26 June 27, 2019
    • Therapies to Restore Consciousness in Patients with Severe Brain Injuries: A Gap Analysis and Future Directions; Neurocrit Care (2021) 35:68–85;
    • Mechanisms Underlying Disorders of Consciousness: Bridging Gaps to Move Toward an Integrated Translational Science; Neurocrit Care (2021) 35:37–54;

  • Treatment of stroke has changed dramatically in the past decade, with the advent of perfusion imaging and an expanded time window for mechanical thrombectomy. Thrombectomy is now standard of care for eligible patients. But while data clearly supports the use of thrombectomy for certain patients with anterior circulation strokes, the benefit of thrombectomy for patients with basilar artery occlusions remains unproven. Today we’ll talk to a vascular neurologist and a neurointerventional surgeon who are trying to better define which patients with basilar artery occlusion may benefit from thrombectomy -- and which patients may not. Series 3, Episode 3



    - Guests: Dr. Carlo Cereda, vascular neurologist, head of the EOC Comprehensive Stroke Center at the Neurocenter of Southern Switzerland and Faculty of Biomedical Sciences, Università della Svizzera Italiana in Lugano & Dr. Jeremy Heit, Assistant Professor of Radiology and of Neurosurgery and the interim Chief of Neuroradiology at Stanford University

    - Interviewer/Producer: Dr. Michelle Johansen, Assistant Professor of Neurology, Johns Hopkins Medicine


    Disclosures: Dr. Heit disclosed that he consults for Medtronic and MicroVention, and consults and is a member of medical and scientific advisory board for iSchemaView, Inc., and Dr. Cereda disclosed that he is a advisory board for iSchemaView, Inc.

  • On today’s show we’ll focus on functional neurological disorder, or FND -- a wide range of conditions including non-epileptic seizures and functional weakness, dystonia and tremor. These conditions are common and can cause serious disability. But what are these conditions, exactly? What have functional neuroimaging and other tools taught us about their pathophysiology, diagnosis, and treatment? Series 3, Episode 2 Featuring:

    - Guest: Dr. Sara Finkelstein, neurologist and specialist in functional neurological disorder at Massachusetts General Hospital

    - Interviewer/Producer: Dr. Adeline Goss, Neurohospitalist at Highland Hospital and the host and executive producer of ANA Investigates

  • Some patients with medically refractory epilepsy are offered surgeries to implant devices that electrically stimulate the nervous system and actually modulate neural networks over time. On this episode of ANA Investigates, Dr. Vikram Rao of the UCSF Weill Institute for Neurosciences discusses how these neurostimulation devices can reduce seizure burden, along with a range of other potential benefits.‌ Series 3, Episode 1.


    • Guest: Dr. Vikram Rao, epileptologist and Associate Professor of Neurology at the UCSF Weill Institute for Neurosciences
    • Interviewer & Producer: Dr. Rohit Das, epileptologist at UT Southwestern Medical Center‌‌

  • Autonomic dysfunction often presents with subtle symptoms affecting multiple organ systems simultaneously. On this episode of ANA Investigates, we discuss bedside evaluation and advanced workup of dysautonomia and how to manage refractory symptoms. Series 2, Episode 11. Featuring:

    • Guest: Safwan Jaradeh, MD, Professor of Neurology, Psychiatry and Behavioral Sciences and Director of the Autonomic Disorders Program at the Stanford Neuroscience Health Center
    • Interviewer/Producer: Megan Richie, MD, Associate Professor, UCSF

  • In July, the World Health Organization released its updated classification of Tumors of the Central Nervous System. The last update was in 2016. The update reflects the increasing role of molecular biomarkers in tumor characterization -- a change that has major implications for how we diagnose and treat patients with brain and spinal cord tumors. Joining us today to help us understand these changes is Dr. Lynne Taylor. Dr. Taylor is a professor of Neurology and Oncology at the University of Washington and co-director of the Alvord Brain Tumor Center at University of Washington Medical Center. Dr. Taylor was interviewed by ANA Investigates producer and neuro-oncologist, Dr. Doug Ney. Series 2, Episode #10

  • In recent years, the Food and Drug Administration approved several new treatments specifically for the treatment of multiple sclerosis and neuromyelitis optica spectrum disorder. But what about neuroimmunological conditions that do not have FDA approved options and require off-label use of immunomodulatory medications -- conditions like neurosarcoidosis, neuro-Behcet’s, or central nervous system involvement of systemic rheumatologic conditions? There is often a lack of rigorous evidence to guide treatment of these conditions, leaving experts to rely on individual or institutional experience. Our guest on this episode is Dr. Jeffrey Gelfand, neuroimmunologist and Associate Professor of Neurology at UCSF. He specializes in treating patients with rare neuroinflammatory conditions, and he’ll talk to us about the new drugs for NMO as well as off-label use of immunomodulatory therapies for a range of neurological conditions. Dr. Gelfand was interviewed by ANA producer Dr. Rohini Samudralwar. Series 2, Episode #9

    Disclosures: Dr. Gelfand receives research support to UCSF for clinical trial from Rosch and Genetech; provides consulting to Biogen

  • For much of the history of neurology, diagnosing a genetic disease meant giving bad news. Genetic meant incurable, often fatal. On past shows, we’ve talked about how this narrative is changing for certain monogenic diseases like Huntington’s Disease, where emerging gene therapies offer hope for a cure. But what hope can the field of neurogenetics offer to patients with more complex diseases with both genetic and environmental risk factors, like Alzheimer’s? Our guest today, Dr. M. Elizabeth Ross, is Professor of Neurology and Neuroscience in the Brain and Mind Research Institute and Director of the Center for Neurogenetics at Weill Cornell Medicine. Her lab works on the genetics of neurologic diseases affecting humans at every stage of the lifecycle. Today she’ll help us understand the role of genetics in a range of neurodegenerative diseases -- and how and when clinicians should incorporate genetic considerations into patient care. Series 2, Episode 8

  • Neurology and psychiatry: two fields, one organ system. Today, we’ll focus on the intersection between the two. We’ll discuss one common psychiatric disease -- depression -- and how new treatments for depression may inform how we treat other neurologic illnesses. ANA Investigates Producer Dr. Rohit Das interviewed Dr. Helen Mayberg, behavioral neurologist at the Icahn School of Medicine at Mt. Sinai, about her pioneering research in circuit-based treatment of depression, particularly deep brain stimulation, or DBS. Series 2, Episode 7

  • Current guidelines for management of carotid stenosis are based on a series of trials dating back to the 1990s. If you ask today’s guests, virtually no other area of neurology is so badly in need of an update. Dr. Seemant Chaturvedi, the Stewart Greenebaum Endowed Professor of Stroke Neurology at University of Maryland School of Medicine, and Dr. Cheryl Bushnell is Professor of Neurology, Vice Chair of Research, Stroke Division Chief at Wake Forest Baptist Health join us for a discussion of the major advances in medical therapy for stroke prevention and why these advances require new trials to refine patient selection for revascularization. They’ll also discuss the growing role of plaque imaging in treatment decisions. Series 2, Episode 6

  • The topic of today’s podcast is tenecteplase. This is a thrombolytic drug that is administered intravenously, for certain patients who present to the hospital with an acute ischemic stroke.  There is mounting evidence that intravenous tenecteplase is at least as safe and effective as intravenous alteplase, the current standard of care in ischemic stroke. Tenecteplase also less expensive and easier to administer. Our guest today is Dr. Bruce Campbell, who has played a pivotal role in the deployment of tenecteplase for stroke. Dr. Campbell was interviewed by Dr. Michelle Johansen, a vascular neurologist at Johns Hopkins. Series 2, Episode 5

  • Less than a year -- that's how long it took between when the novel coronavirus emerged and when a vaccine was available to prevent it. This incredible speed of vaccine development exemplifies scientific innovation in a time of crisis. There is increasing vaccine acceptance among the public, but questions about target populations, mechanisms, and side effects remain. Neurological complications have been documented with other vaccines, and there have been some possible complications observed with the vaccines for Covid-19. Our guest on this episode, Dr. Avindra Nath, is a physician-scientist who specializes in neuroimmunology and infections of the nervous system. He is the intramural Clinical Director of the National Institute of Neurological Disorders and Stroke at the National Institutes of Health. Series 2, Episode 4

    The resources referenced during the interview may be found at the following links: &


  • The past year has forced us all to contend with the devastating power of infectious disease. The daily, mortal fear of infection is a new experience for many people in the developed world. But that fear characterizes life for millions of people around the globe -- including those who have already lived through plagues or lost loved ones to curable infections. These infections disproportionately target those living in poverty. Many have epidemic or pandemic potential. And many have neurological manifestations. In this episode, Dr. Adeline Goss interviews Dr. Farrah Mateen, a neuroinfectious disease specialist at Massachusetts General Hospital in Boston and her recent work with a group of colleagues to compile the neurological manifestations of the 20 diseases with epidemic or pandemic potential recognized by the World Health Organization. Season 2, Episode 3

  • In this episode, we'll introduce you to the next generation of ANA scientists. You may remember a new event at this year's ANA conference called the Emerging Scholars sessions, where we heard presentations from our junior ANA members about their cutting edge research. Those talks were judged based on scientific merit and presentation quality.... and today we'll introduce you to the four winners. 

    This year's Emerging Scholars are Dr. Gus Davis, Dr. Juliane Gust, Dr. Jenn Orthmann-Murphy, and Dr. Xilma Ortiz-Gonzalez. They were interviewed by Dr. Michelle Johansen, a vascular neurologist and assistant professor of neurology at Johns Hopkins. Series 2, Episode 2

  • This is an exciting moment in the management of a devastating neurologic condition -- Huntington's Disease. As we know, this genetic disease often hits patients at the prime of life and, because it is autosomal dominant, can be haunting for affected families. As we'll discuss today, new developments in biomarkers and therapies for Huntington's are converging into a more hopeful picture for those affected. In this episode, we’ll hear from two Huntington Disease experts -- Dr. Jee Bang, Clinical Director of Johns Hopkins Huntington Disease Center of Excellence and Assistant Professor of Neurology... and ANA investigates producer Dr. Danny Bega, Director of the Northwestern Medicine Huntington Disease Center of Excellence and Associate Professor of Neurology.

  • Today’s show is on the science of sleep. Specifically, how sleep – or too little of it – affects the growing brains of adolescents. Why do teenagers stay up so late? What sleep schedules are optimal for their learning? We’ll hear from two world experts in adolescent sleep -- Dr. Beth Malow and Dr. Frances Jensen. Dr. Malow is a Professor of Neurology and Pediatrics at Vanderbilt, and the Burry Chair in Cognitive Childhood Development. She directs the sleep division at Vanderbilt University Medical Center and has been a major advocate for policies that promote healthy adolescent sleep patterns. Dr. Jensen is Professor and Chair of Neurology at the Perelman School of Medicine at the University of Pennsylvania, and is President Elect of the American Neurological Association. She has researched the mechanisms of epilepsy, stroke, and adolescent brain development, and is the author of the book “The Teenage Brain.” Drs. Malow and Jensen were interviewed by ANA Investigates producer and UCSF Neurohospitalist, Dr. Megan Richie. Series 1, Episode 15

  • This is an exciting moment in the field of neuro-genetics. Advances in gene therapy are opening up new avenues to treating certain genetic forms of otherwise fatal and incurable diseases like ALS and dementia. This may give genetics a bigger role in the daily clinical practice of many adult neurologists. Today we'll learn about this frontier in neuro-genetics from Dr. Bryan Traynor at the National Institute on Aging. He was interviewed by ANA member and neuromuscular specialist at Johns Hopkins, Dr. Ricardo Roda. Series 1, Episode 14

  • Today, in recognition of Alzheimer’s and Brain Awareness month, we'll hear from Dr. David Holtzman, professor and chair of neurology at Washington University in St Louis. Dr. Holtzman's work has helped to clarify the relationship between Apolipoprotein E4, or apoE4, and Alzheimer's disease. He is also working to develop CSF biomarkers for Alzheimer's, and he has worked on the development of anti-amyloid beta and anti-tau antibodies for now being evaluated through clinical trials in patients with the disease. ANA’s education manager, Jen Hurley, spoke with Dr. Holtzman about the current state of research in biomarkers for Alzheimer’s disease. Dr. Holtzman wishes to disclose that he is a co-founder with equity in the company C2N Diagnostics, a biotech start up focusing on blood biomarkers for AD; he is on the Scientific advisory board of C2N Diagnostics and Denali Therapeutics, and consults for Genentech and Idorsia. Series 1, Episode 13

  • During this special jointly-produced ANA-AUPN episode, Dr. Clifton Gooch, AUPN president and Dr. Justin McArthur, ANA president discuss how their institutions and departments are approaching operations amid COVID-19, as well as sliver linings they see resulting from the unavoidable shift to virtual operations both clinically and in research. Series 1, Episode 12 **Join the ANA today to attend ANA2020 Virtually for free***

  • In this episode, we’ll visit the frontiers of vascular neurology, discussing an important but little-understood category of strokes — embolic strokes of undetermined source, or ESUS. We’ll hear from Dr. Hooman Kamel, division chief of neurocritical care at Weill Cornell Medicine. Dr. Kamel is a co-principal investigator for the ARCADIA trial, which is testing anti-thrombotic strategies in patients with cryptogenic stroke and atrial cardiopathy. He was interviewed by ANA Member Michelle Johansen, a vascular neurologist and assistant professor of neurology at Johns Hopkins. Series 1, Episode 11

  • The coronavirus pandemic has dramatically changed neurologists' lives -- both at work and at home. Neurologists are taking on new roles and interfacing with patients in new ways, while our work poses new risks to us and our families. How are clinical neurologists adapting and coping in a time of such change? That's the focus of today's special episode. Dr. Adeline Goss was joined by three co-producers on ANA Investigates: Drs. Romer Geocadin, Jim Siegler, and Megan Richie to discuss their experience. Series 1, Episode 10

  • In this episode, Dr. Jim Siegler interviews Dr. Marc Simard on the management of patients with large hemispheric strokes and cerebral edema. This is a particularly devastating condition: the mortality rate is as high as 50-80 percent at 1 year with medical management alone. Decompressive craniectomy can improve survival for some patients, but most survivors are left with major disability. To date, not a single intervention has been shown to improve functional outcomes for these patients. The search for such a treatment is ongoing -- and that’s the topic of our conversation today. Series 1, Episode 9

  • ANA Investigates podcast is brought to you by ANA members, for ANA members, and that is never more true than it is today. In response to this ever-evolving coronavirus pandemic, ANA members have come together to bring you this special episode of ANA investigates recorded this morning addressing the neurological impact of COVID-19. As the number of infections swells worldwide, more patients with the virus have been noted to have neurological signs. Yet the precise relationship between the COVID19 and these symptoms remains unclear. We asked ANA member Dr. Danny Bega to discuss the neurology of COVID-19 with his colleague and neuroinfectious disease specialist Dr. Igor Koralnik. Series 1, Episode 8

  • In this episode, we’ll delve into the medically and legally complex topic of cannabis. The legal landscape around marijuana has changed in the US in the past 15 years. Many of our patients now have legal access to products derived from cannabis, and they are turning to physicians for advice on whether these products can treat their neurologic conditions. Products derived from cannabis have been studied in a range of neurologic diseases. One product has shown modest efficacy (and is approved for use) in patients with Dravet Syndrome and Lennox-Gastaut Syndrome. The data for using cannabis-derived products in certain other neurologic conditions is less convincing and the use of these products remains controversial. How should we council our patients about this? Dr. Adeline Goss interviewed Dr. Michelle Cameron, associate professor at Oregon Health and Science University and Multiple Sclerosis (MS) specialist, on the use of medical use of cannabis and cannabinoids, with an emphasis in their use in treating the symptoms of MS. Dr. Cameron disclosed a consulting relationship with Greenwich Biosciences. Series 1, Episode 7

  • This is an exciting time in the treatment of neurologic disease -- a period of rapid innovation and discovery. And, as a result, more and more academic neurologists and neuroscientists are partnering with the corporate world and others to bring their discoveries to market. On this episode of ANA investigates, Dr. Clifton Gooch, Professor and Chair of Neurology at the Morsani College of Medicine at the University of South Florida explores the complex world of patents and intellectual property in academic neurology in an interview with Dr. Terry Hunter, the senior licensing manager of technology transfer at the University of South Florida Office of Research and Innovation. Series 1, Episode 6

  • This month we’ll have the first episode exploring the career paths of some of the most inspiring leaders in our field. During ANA2019, Dr. Romer Geocadin interviewed Dr. Walter Koroshetz, the Director of the NINDS about his journey. Dr. Koroshetz's shares insights and give advice for those that wish to follow in his footsteps. Series 1, Episode 5

  • This month we'll explore a topic that's more social science than neuroscience. We address implicit bias, explicit bias and our ability to change each of our biases. Dr. Jim Siegler, assistant professor of neurology at Cooper University interviews Dr. Allison Willis, associate professor of neurology and epidemiology at University of Pennsylvania Perelman School of Medicine. Series 1, Episode 4.

  • This month, we'll have part two of our two-part series on unbiased diagnostics in neurologic disease. As you may remember from our first episode, UCSF neurohospitalist Megan Richie interviewed Dr. Michael Wilson, a neuro-immunologist at UCSF, about a technique called metagenomic next generation sequencing, or mNGS. mNGS is a way of searching all of the genetic material in a CSF sample for the presence of any non-human organisms. This approach is thought of as “unbiased” – it allows us to search for any infectious organism present in the central nervous system, rather than coming up with a list of possible infections and testing for each of them individually. Today, we’re back with Megan Richie for part 2 of this series, interviewing Dr. Samuel Pleasure about autoantibody testing and hearing more from Dr. Wilson comparing the methods and future plans. Series 1, Episode 3.

  • This episode is the first of a two-part episode on unbiased diagnostics in neurologic disease. In this episode, UCSF's Dr. Megan Richie sat down with UCSF's Dr. Michael Wilson, a neuro-immunologist specializing in infectious diseases of the central nervous system. They spoke about the unbiased technique called metagenomic next generation sequencing, or mNGS, a technique developed through the UCSF Center for Next-Gen Precision Diagnostics. Series 1, Episode 2.

  • At a time when support for basic and translational science needs a strong voice and the burden of neurological disease is growing, the ANA is the champion of neurological research and the ally of all physicians and scientists who strive to make a difference through careers that combine discovery, education, and clinical care.

    In pursuit of this mission, the ANA introduces a new podcast series, ANA Investigates. Every month you’ll hear new content, the latest content, on topics in neurology, neuroscience,the basic sciences, quality improvement, patient care, clinical research, and more - all brought to you by the American Neurological Association. The ANA. Featuring interviews with leaders in the field, clinical researchers, experts, and innovators. Find out more on the ANA website: